AbZelectPRO™-KO+: Advanced GS Knockout ADCC+ CLD Platform

ADCC+ CLD platform is a double knockout of both glutamine synthetase (GS) & fucosyl-transferase genes, which increases potency and clinical efficacy of antibodies.

Watch Video Download Info Sheet

Enhanced platform that increases potency & efficacy of Afucosylated Proteins. Discover AbZelectPRO™-KO+

AbZelectPRO™-KO+: Increases antibody binding to CD16a receptor

Increases antibody binding to CD16a receptor

AbZelectPRO™-KO+: Stability shown up to at least 60 generations

Stability shown up to at least 60 generations

AbZelectPRO™-KO+: Enables the production of 100% fucose-free proteins

Enables the production of 100% fucose-free proteins

AbZelectPRO-KO+™ fuses Abzena’s extensive cell line development expertise with Revvity’s proven CHOSOURCE™ ADCC+ host line and ProteoNic’s high-output 2G UNic® expression vector. The CHOSOURCE™ ADCC+ mammalian cell line is a dual GS / FUT8 knockout CHO-K1 line that abolishes core fucosylation, dramatically boosting CD16a binding and downstream immune-cell killing (ADCC). Layered onto this is, the 2G UNic® vector provides exceptional transcriptional and translational efficiency while maintaining the familiar AbZelectPRO™ CLD process. Long-term stability is built in, as clones have maintained over 95% productivity through at least 60 generations.

Our New AbZelectPRO™-KO+ Platform

AbZelectPRO™-KO+: Advanced GS Knockout ADCC+ CLD Platform - Abzena

Long-term stability is built in, as clones have maintained over 95% productivity through at least 60 generations. The CHOSOURCE™ lineage already underpins four marketed therapeutics and more than 90 regulatory filings, giving your CMC package instant credibility.

How can AbZelectPRO-KO+ help you maximize the potential of your cell line?

  • Potency gains – up to 40-fold stronger CD16a engagement vs. fucosylated IgG
  • Stable performance – productivity >95 % maintained through ≥60 generations
  • Streamlined manufacturing – gives consistent pools, shrinking screening & tox timelines
Contact Us

Supporting a Broad Range of Diverse Formats

AbZelectPRO™: Enhanced Cell Line Development - Abzena

Our experienced CLD team of experts recognizes the unique challenges posed by some formats & novel modalities.

We can make the complex possible by supporting a broad range of diverse modalities:

  • Monoclonal & Bispecific Antibodies
  • Fc-Fusion Proteins
  • Antibody–Drug Conjugates
  • Multispecific / Multivalent Formats
  • Novel Glyco-Engineered Scaffolds
  • Complex Fusion Proteins

Revvity’s Enhanced CHOSOURCE ADCC+ Cell Line

A glycoengineered GS-KO CHO-K1 host with an additional FUT8 knockout, CHOSOURCE ADCC+ eliminates core fucose to intensify FcγRIIIa (CD16a) affinity and ADCC potency, enabling lower clinical doses and greater therapeutic impact.

Key features:

  • Dual GS / FUT8 knockout—no fucosylation, proven GS selection background
  • Comprehensive cell-line history pack with >90 regulatory filings
  • Adaptable to any protein architecture and multiple media/feed regimes
  • Established cGMP lineage supporting at least 4 marketed products

Powered by ProteoNic’s 2G UNic® Vector Technology

We enhance the productivity of AbZelectPRO-KO+ by partnering Revvity’s CHOSOURCE™ cell line with ProteoNic’s 2G UNic® premium expression vector technology. The vector offers the following benefits:

  • Optimized expression cassettes to maximize productivity through dual promoters combined to drive increased mRNA transcription per gene copy
  • Highly stable clones maintaining productivity beyond 90 generations through epigenetic stabilization, which reduces gene silencing for greater stability
  • Higher ribosome affinity for improved translation with optimized mRNA transport and mRNA stability allowing for more protein per mRNA molecule
  • Efficient GS selection marker compatible with CHOSOURCE™ cell Line
  • Proven track record with multiple programs moving towards regulatory approvals
  • Demonstrated success across numerous programs advancing toward licensure

Leverage our enhanced platform that increases the potency and efficacy of Afucosylated Proteins. Achieve more with AbZelectPRO™-KO+.

Ready to move forward? Contact Abzena

Related Insights

Whitepaper: Random Integration vs. Semi-Targeted Integration

Abzena's CLD experts explore two primary approaches - random integration and semi-targeted (or transposase) integration.

Learn More

Case Study: CHO Cell Line Performance with 2G UNic® Technology

Discover our case study that assesses the impact of 2G UNic® vector technology on protein expression in CHO cell lines

Learn More

Blog: AbZelectPRO™ - The Fast-Tracked CLD Platform of the Future

ProteoNic & Abzena experts discuss the benefits of our enhanced cell line development platform, AbZelectPRO™.

Learn More